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Abstract 
Extensive in vitro phosphorylation of a purified preparation of control human brain tau consistently produces four rather than, as previously 
believed, three tau species on SDS-PAGE. The species thus generated are shifted on SDS-PAGE to positions that match those of PHF-tau isolated 
from Alzheimer’s disease brain. A mixture of recombinant human tau isofonns phosphorylated by GSK-3B gave similar results to those obtained 
with control human brain tau. In vitro phosphorylation of the individual recombinant isoforms by GSK-3/I showed that the four bands of PHF-tau 
are likely to consist of isoforms 3R,O alone; 4R,O with 3R,29; 4R,29 with 3R,58 and 4R,58 alone. 
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1. Introduction 
Neurofibrillary tangles and senile plaques are the two 
histopathological hallmarks of Alzheimer’s disease 
brain. Neurofibrillary tangles consist of paired helical 
filaments (PHF) a major constituent of which is the mi- 
crotubule-associated protein, tau (PHF-tau) [l-5]. PHF- 
tau is composed of several tau isoforms that are in a 
hyperphosphorylated state compared to tau from con- 
trol human brain [6-lo]. PHF-tau usually separates into 
three major species on SDS-PAGE with a fourth and less 
prominent, but often observable, band possessing a 
lower mobility than the three main bands. 
Tau promotes tubulin assembly and stabilizes micro- 
tubules in vitro (see [l l] for review). Phosphorylation 
regulates the ability of tau to bind to microtubules and 
promote tubulin assembly [12-151. Some of the abnor- 
mal phosphorylation sites on PHF-tau have been identi- 
fied [l&19] and these are mainly at serine-proline and 
threonine-proline motifs. For this reason, several mem- 
bers of the proline-directed protein kinase family, 
including glycogen synthase kinase-3ol (GSK-3a) and p 
(GSK-3/?), have been investigated for their ability to 
phosphorylate tau in vitro [20-271. 
*Corresponding author. Fax: (44) (71) 277 1390. 
Abbreviations: SDS-PAGE, sodium dodecyl polyacrylamide gel electro- 
phoresis; DTT, dithiothreitol; PHF, paired helical filament; GSK-3, 
glycogen synthase kinase-3; EGTA, ethylene glycol-bis-Gg-aminoethyl 
ether)N,N,N’,N’-tetraacetic acid; PMSF, phenylmethylsulfonyl fluo- 
ride; ATP, adenosine 5’-triphosphate. 
The highest level of expression of both GSK-3 
isoforms is found in brain [28]. GSK-3a and GSK-3/? are 
present in neurones of both control and Alzheimer’s dis- 
ease brain [20] and have been reported to co-purify with 
PHF [21]. We have previously shown that a single 
isoform of recombinant human brain tau is 
phosphorylated in vitro by both GSK-301 and GSK-3B 
in a manner that generates the characteristic shift in 
mobility of tau on SDS-PAGE and also induces 
phosphorylated epitopes on tau which are associated 
with PHF [20]. In this report, we show that PHF-like tau 
comprising four electrophoretically distinct species can 
be generated, after 24 hours incubation with GSK-3p, 
from both human brain tau isolated from normal brain 
and from a mixture of recombinant human tau isoforms. 
Phosphorylation of the individual recombinant isoforms 
of tau enabled us to assign probable identities to the four 
PHF-tau species that are different from previous assign- 
ments [7,9,10]. The phosphorylation state of GSK-3/?- 
phosphorylated tau protein was assessed using a panel 
of phosphate-dependent and -independent monoclonal 
and polyclonal antibodies and was demonstrated to have 
an antigenic profile similar to that of PHF-tau. 
2. Materials and Methods 
2.1. Purtjication of talc from control human brain 
Tau was prepared from control human brain (obtained from the 
MRC Alzheimer’s Disease Brain Bank, Institute of Psychiatry, Lon- 
don) by homogenizing 1 g grey matter from cerebral cortex in 2 ml of 
100 mM MES, pH 6.5, containing 1 M NaCI, 0.5 mM MgCl,, 1 mM 
EGTA, 1 mM PMSF, 10 mM sodium pyrophosphate and 20 mM 
sodium fluoride. The homogenate containing a-mercaptoethanol was 
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heated to 100°C for 10 min and centrifuged at 20,000 x g,, for 35 min 
at 4°C. The heat-stable fraction was precipitated by addition of satu- 
rated ammonium sulphate solution to 35% saturation and centrifuga- 
tion at 20,000 x g,, for 35 min at 4°C. The precipitate was dissolved in 
100 ,uI of 50 mM MES, pH 6.5 containing 1 mM DTT and loaded onto 
a Mono S column (Pharmacia) equilibrated in the same buffer. Tau was 
eluted with a linear gradient (0.05 M to 0.5 M) of NaCl and finally 
purified on a reversed-phase Cl8 column (Vydac) with a gradient of 
acetonitrile containing 0.1% (v/v) trifluoroacetic acid. Fractions con- 
taining tau were detected by Western blotting with the monoclonal 
antibody Tau.1. 
2.2. Preparation of recombinant human tau 
cDNA from the six human tau isoforms in the plasmid pRK 172 were 
expressed in E. coli (BL21 DE3) [29] and are referred to as 3R,O; 4R,O; 
3R,29; 4R,29; 3R,58 and 4R,58 (see also Fig. 4) following the nomen- 
clature in [29]. Tau protein was purified by a modification of the 
method of Scott et al. [30]. The bacterial cell suspension (500 ml) was 
pelleted at 3,320 x g,, for 20 min at 4°C resuspended in 50 mM MES, 
pH 6.5 and centrifuged as above. The pelleted cells were weighed and 
resuspended (10 ml/g pellet) in 50 ml 50 mM MES, pH 6.5, containing 
1 mM PMSF, 1 mM DTT, 1 mM EGTA, 10 mM sodium pyro- 
phosphate and 20 mM sodium fluoride. The suspension was sonicated 
for 5 min at room temperature and centrifuged at 29,900 x g,,, for 20 
min at 4°C. NaCl was added to the supernatant to produce a final 
concentration of 0.5 M, the mixture was heated to 100°C for 10 min 
and centrifuged at 182,000 x g,, for 2 h at 4°C. The heat-stable super- 
natant was precipitated with ammonium sulphate (35% saturation) and 
centrifuged at 16,400 x g,, for 20 min at 4°C. The pellet was resus- 
pended in 3 ml 50 mM MES, pH 6.5, containing 1 mM DTT and 50 
mM NaCl and dialysed overnight at 4°C against 500 ml of the same 
buffer. The dialysate was loaded onto a Mono S column and eluted with 
a linear gradient (0.05-0.5 M) of NaCl 
2.3. Purjfication of PHF-tau 
PHF-tau was prepared from Alzheimer’s disease brain essentially 
according to the method of Brion et al. [31]. 
2.4 Activity of GSK-3p 
The enzyme GSK-3/I was assayed by incubating 5 ,uI of diluted 
enzyme with 50 ,uM ATP (containing 1 ,&i = 0.037 MBq [Y-~*P]ATP), 
5 mg/ml bovine-serum albumin, IO mM MgCI,, 1 mM EGTA, I mM 
dithiothreitol. 10 &ml hendrin and 8 uM GS-I neutide in 25 mM 
Tris-HCl, pH 7.4: at 30°C’ in a volume of 20 @.&After 30 min, the 
reaction was terminated by adding 20 ,uI of 20% (w/v) trichloroacetic 
acid containing 5 mM ATP, standing on ice for 5-10 min and centrifug- 
ing on a microfuge. The supernatant (25 ,uI) was pipetted onto pieces 
of phosphocellulose paper (P81 Watman), washed 5 times in 0.5% (v/v) 
phosphoric acid, and immersed in water for Cerenkov counting. The 
GSK-3/3 sample used in experiments in which tau was phosphorylated 
had an activity of 36 pmol of phosphate transferred per minute per ~1 
of stock enzyme. 
The GS-I peptide (described in [32]) was synthesised as the 
phosphopeptide with its casein kinase 11 site fully phosphorylated. 
2.5 Phosphorylation of tau by GSK-3/3 
Control human brain tau and individual recombinant human tau 
isoforms (8 pup) were incubated with 4 ~1 of GSK-3B (prepared as 
described in 1321) in 20 mM HEPES buffer. DH 7.5. containing 5 mM 
MgCI,, 10 PM l&peptin, I ,uM pepstatin, I’mM PMSF, 0.5 mM DTT, 
5 ,uM okadaic acid, 1 ,uM sodium orthovanadate and 3 mM ATP, for 
24 h at 30°C. Appropriate controls containing heat-inactivated enzyme 
were incubated in parallel. The reaction was stopped by heating at 
100°C for 5 min. Samples were analysed by SDS-PAGE (10% gels) [33] 
and Western blotting [8]. Blots were probed with the monoclonal 
antibodies SMI 31, SMI 310 and SMI 34 (Affiniti Research Products 
Limited), which recognise phosphorylated epitopes and SM133 which 
recognises an unphosphorylated epitope on tau [17,34]. Monoclonal 
antibodies RT97, BFIO, 8D8 and 1215 [35,36] recognise 
phosphorylated epitopes on tau, the exact location of which is known 
only for 8D8 as serine 396 (numbering corresponds to the largest 
isoform of human brain tau) [20]. 5E2-is a phosphate-independent 
monoclonal antibody to tau [37]. The monoclonal antibody, AT8 [38], 
recognises phosphorylated serine 202 on tau [39] whereas Tau.1 [40] 
recognises serine 199 and/or 202 only when they are non- 
phosphorylated [41,42]. The polyclonal antibody to tau has been 
previously described [43]. 
3. Results 
Following phosphorylation by GSK-3B, recombinant 
human tau and control human brain tau (Fig. 1, lanes 
14) shifted to align with PHF-tau isolated from Alz- 
heimer’s disease brain (Fig. 1, lane 5). Both types of 
phosphorylated tau protein as well as PHF-tau appeared 
as four bands when immunolabelled with the polyclonal 
antibody to tau (Fig. 1, lanes 335). 
GSK-3jCphosphorylated human brain tau was 
strongly immunolabelled by 5E2 and the phosphate-de- 
pendent antibodies 1215, 8D8, RT97, BFlO, AT8, SMI 
31, SMI 310 and SMI 34 (Fig. 2A). The reactivity of tau 
with AT8, 8D8, SMI 31 and SMI 310 indicates the pres- 
ence of phosphorylated serines 202, 396 and 404 in tau. 
SMI 34 which is both phosphorylation and conforma- 
tion-dependent reacted strongly with phosphorylated 
human brain tau suggesting that GSK-3/I had generated 
both the necessary phosphorylated residue(s) and the 
required conformational change. SMI 33 had a de- 
creased immunoreactivity for the GSK-3jC 
phosphorylated protein indicating that serine 235 was 
phosphorylated to some extent but not completely. 
Tau.1 was only immunoreactive with the unphosphor- 
ylated protein indicating that possibly both serines 199 
and 202 are phosphorylated by GSK-3B. 
The pattern of immunoreactivity generated by phos- 
phorylation with GSK-3/I of both human brain tau and 
recombinant human tau is very similar. Human brain 
tau, incubated with heat inactivated GSK-3P, showed 
some immunoreactivities with antibodies 1215 and 8D8, 
and a strong reactivity with RT97 and BFlO (Fig. 2A), 
indicating that the respective epitopes are at least par- 




Fig. 1. Western blot labelled with polyclonal antibody to tau. Lane l- 
all six recombinant human tau isoforms; lane 2- purified control human 
brain tau; lane 3- the same sample as in lane I, phosphorylated by 
GSK-3/I; lane 4- the same sample as in lane 2, phosphorylated by 
GSK-3/I; lane 5- PHF-tau. Molecular weight markers are indicated by 
arrowheads and correspond to phosphorylase b (97.4 kDa), catalase 
(58.1 kDa) and alcohol dehydrogenase (39.8 kDa). 
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Fig. 2. Immunoblots of control human brain tau (panel A) and recombinant human brain tau (panel B) incubated with heat-inactivated GSK-3/3 
(lanes 1) or with active GSK-3/3 (lanes 2). Blots were labelled by the antibodies indicated. 
unphosphorylated recombinant human tau had a very 
weak reactivity only with 1215 (Fig. 2B). 5E2 labelled 
recombinant and human brain tau in the same way 
(Fig. 2A,B). Thus, the pre-existing phosphorylated sites 
in human brain tau do not appear to prime for phospho- 
rylation by GSK-3/?, as has been found necessary for 
some substrates, at the epitopes detected by this panel of 
monoclonal antibodies [44-46]. 
Phosphorylated human brain tau showed either 3 or 
4 bands on the blots, depending on the antibody. The 
fourth (upper) band is detected by the polyclonal anti- 
body to tau (Fig. l), 1215, 8D8, RT97 and SMI 310 (Fig. 
2A), whereas all the antibodies recognise the fourth band 
generated from the recombinant protein (Fig. 2B). The 
stronger intensity of the slowest migrating band of 
phosphorylated recombinant human tau (Fig. 2B) com- 
pared with phosphorylated human brain tau (Fig. 2A) 
probably results from the individual isoforms being 
mixed in similar quantities, whereas human brain tau 
contains relatively less of both 3R,58 and 4R,58 isoforms 
and hence are detected less well by certain antibodies 
after phosphorylation. Several antibodies also detected 
numerous bands migrating faster than the smallest au 
isoform and these are the result of some limited proteol- 
ysis of brain tau and recombinant au. 
Individual recombinant human tau isoforms were in- 
cubated with GSK-3p or with heat-inactivated enzyme 
as control (Fig. 3A). Following phosphorylation, the 
smallest au isoform, 3R,O (Fig. 3A, lane 3) migrated to 
the same position or very close to that of the lower band 
of PHF-tau (Fig. 3A, lanes 1, 8 and 15). Isoforms 4R,O 
and 3R,29 (Fig. 3A, lanes 5 and 7, respectively) aligned 
close to (from bottom to top on SDS-PAGE and Fig. 4) 
the second band of PHF-tau, with 4R,O migrating 
slightly above 3R,29. Isoforms 4R,29 and 3R,58 (Fig. 
3A, lanes 10 and 12, respectively) aligned with the third 
band of PHF-tau. Finally, phosphorylated isoform 
4R,58 (Fig. 3A, lane 14) aligned with the fourth and 
slowest migrating band of PHF-tau. Note that not all tau 
isoforms have an equal mobility shift on SDS-PAGE; the 
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Fig. 3. (A) Immunoblots labelled with polyclonal antibody to tau, showing: PHF-tau in lanes 1, 8 and 15; unphosphorylated single recombinant au 
isoforms 3R,O; 4R,O; 3R,29; 4R,29; 3R,58 and 4R,58 in lanes 2, 4, 6, 9, 11 and 13, respectively; and the corresponding isoforms phosphorylated by 
GSK-3/S in lanes 3, 5, 7, 10, 12 and 14, respectively. Lanes l-8 and 9-15 were electrophoresed separately, molecular weight markers are indicated 
for both gels and are as in Fig. 1. (B) Immunoblot labelled with polyclonal antibody to tau showing the reconstitution of bands matching the 
electrophoretic mobility of PHF-tau (lanes 1 and 7) from combinations of phosphorylated tau isoforms. 3R,O alone (lane 2); 4R,O with 3R,29 (lane 
3); 4R,29 with 3R,58 (lane 4); 4R,58 alone (lane 5) and the mixture of all six isofonns (lane 6). Note that the slowest migrating PHF-tau species is 
not always visible and may depend on both the antibody used and the amount loaded onto the gel. 
presence of an additional tubulin-binding repeat appears 
to produce a greater mobility shift than does the presence 
of an insert in the N-terminal half of tau. 
The individually phosphorylated recombinant tau 
isoforms were mixed to see if the SDS-PAGE pattern of 
PHF-tau could be exactly mimicked and to check that 
there was not some kind of interaction between the 
isoforms when phosphorylated together since individu- 
ally phosphorylated 4R,O migrated slightly above 
phosphorylated 3R,29. Isoform 3R,O was run on its own 
(Fig. 3B, lane 2) and aligned with the fastest PHF-tau 
band (Fig. 3B, lane 6). When mixed, isoforms 4R,O and 
3R,29 ran as a single band on SDS-PAGE aligning with 
the second fastest band of PHF-tau, and the mixture of 
isoforms 4R,29 plus 3R,58 aligned as a single band with 
the third fastest-migrating species of PHF-tau (Fig. 3B, 
lanes 3 and 4). Isoform 4R,58 (Fig. 3B, lane 5) aligned 
with the slowest-migrating species of PHF. Thus, with 
regard to electrophoretic mobility, the PHF-tau pattern 
can be reproduced by GSK-3j6phosphorylated human 
brain tau and recombinant human tau and the relation- 
ship between the individual tau isoforms and the PHF- 
tau species is illustrated schematically in Fig. 4. 
4. Discussion 
The isoform composition of PHF-tau has only been 
partially resolved because PHF-tau sometimes eparates 
as three and sometimes as four bands on SDS-PAGE 
and attempts to assign isoforms to each species have only 
been made for the three principal PHF-tau bands. The 
fourth, slowest migrating, species of PHF-tau is always 
present in much smaller amounts compared to the other 
three main bands. Here we have described a method to 
generate, from recombinant human tau and control 
human brain tau, PHF-like-tau comprised of four spe- 
cies on SDS-PAGE and closely resembling PHF-tau iso- 
lated from Alzheimer’s disease brain. We found no dif- 
ference in the phosphorylation of the control human 
brain tau or recombinant human tau as both substrates 
produced species of apparent molecular mass equal to 
those of PHF-tau on SDS-PAGE. It is not possible to say 
from this study whether the presence of phosphate on tau 
isolated from human brain altered the kinetics of phos- 
phorylation by GSK-3p with this substrate compared to 
the recombinant protein. Individual recombinant tau 
isoforms phosphorylated by GSK-3p had characteristic 
migrations on SDS-PAGE which matched, either singly 
or in pairs, with one or other of the four bands of PHF- 
tau. 
We have previously shown that CAMP-dependent pro- 
tein kinase (PKA) also induces a marked reduction in the 
electrophoretic mobility of recombinant and human 
brain tau [47]. However, when we incubated human 
brain tau or a mixture of all six recombinant human tau 
isoforms with PKA under the conditions described here, 
we did not generate phosphorylated tau with a pattern 
resembling that of PHF-tau (data not shown). Hence, the 
migration of PHF-tau on SDS-PAGE is dependent upon 
a specific pattern of phosphorylation which can be repro- 
duced in vitro by GSK-3/I but not by PKA. However, we 
cannot exclude the possibility that other kinases such as 
cdk5 [48,49], 35 kDa/41 kDa protein kinase [50], MAP 
kinase [51] or other, as yet unidentified, protein kinases 
might also be able to phosphorylate tau in a manner 
which generates both the precise shift in electrophoretic 
mobility and the immunoreactivity with antibodies that 
recognise PHF-tau. 
The PHF-like-tau generated by in vitro phosphoryla- 








Fig. 4. Schematic representation of the six human tau isoforms and PHF-tau. GSK-3B-phosphorylated tau isoforms align with each of the four 
PHF-tau species as indicated by the arrows. 
tion suggests that the four species of PHF-tau are com- 
posed of isoforms 3R,O alone; 4R,O with 3R,29; 4R,29 
with 3R,58; and isoform 4R,58 alone (Fig. 4). The tau 
isoforms isolated from control human brain are not all 
present in equal amounts. Isoforms 4R,O, 3R,29 and 
4R,29 are more abundant han 3R,O, which is itself more 
abundant than 3R,58 and 4R,58. Dephosphorylation of 
PHF-tau using alkaline phosphatase shows that all six 
tau isoforms are present in PHF-tau in the relative quan- 
tities described above [29]. Our model suggests that the 
second band of PHF-tau is composed of both isoforms 
4R,O and 3R,29 which could explain why this band is 
always the most abundant on SDS-PAGE. The fourth 
and slowest migrating PHF-tau band corresponds to 
isoform 4R,58 which is one of the two least abundant 
isoforms. The first and third PHF-tau bands usually 
have similar intensities on SDS-PAGE and this observa- 
tion again fits with the composition of the model de- 
scribed here. It was previously suggested that PHF-tau 
was composed of (3R,O plus 4R,O), (3R,29 plus 4R,29) 
and (3R,58 plus 4R,58) for the fastest migrating, the 
middle and the slowest migrating bands of PHF-tau, 
respectively [lo]. This conclusion was based on labelling 
with antibodies specific for certain tau isoforms and the 
composition suggested here would give the same im- 
munoreactive profile with the antibodies used in that 
study. 
We found that RT97 always labelled the four bands 
of both phosphorylated control brain and recombinant 
tau. This result contrasts with RT97 labelling of PHF- 
tau in which only the band of lowest apparent molecular 
mass is unlabelled by RT97 [31]. The discrepancy in 
labelling by RT97 indicates that although the 
phosphorylated tau generated in vitro by GSK-3/3 is very 
similar to PHF-tau, it may not be identical. Under the 
conditions used of extensive phosphorylation of tau in 
vitro by GSK-3/I, it is possible that additional RT97- 
reactive sites are generated. However, although the pre- 
cise phosphorylation pattern of in vitro-generated PHF- 
like tau may not be identical to PHF-tau isolated from 
Alzheimer brain, the remarkable similarity in electro- 
phoresis profile of these forms of tau implies that sites 
essential for producing the necessary changes in electro- 
phoretic mobility are generated by GSK-3p. 
We propose therefore that PHF-tau comprises four 
bands on SDS-PAGE and that the isoform composition 
of the individual bands is different from that previously 
suggested. Our results also imply that the conforma- 
tional changes necessary for the reduction in electro- 
phoretic mobility of PHF-tau can be generated by GSK- 
38 alone and does not require priming by another 
protein kinase. 
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